Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL) has received a Notice of Allowance from the USPTO for a patent covering its Deep Intracranial Frequency Stimulation (DIFS™) technology for treating substance use disorders. The patent, titled 'Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD),' encompasses treatment for opioid, alcohol, cocaine, and methamphetamine use disorders.

The DIFS™ technology represents a non-invasive, drug-free approach that aims to modulate neural pathways associated with addiction and withdrawal symptoms. This technology could offer an alternative to traditional medication-assisted treatment (MAT) and behavioral therapy, potentially avoiding their associated challenges like accessibility issues and side effects.

Positive

• Secured USPTO patent allowance strengthening intellectual property portfolio
• Technology offers potential alternative to traditional addiction treatments
• Expands addressable market to multiple substance use disorders

Negative

• Technology still in development phase with unproven efficacy
• No mention of clinical trial results or regulatory approvals
• Faces competition from established treatment methods

Insights

Medical Technology Expert

Nexalin's Notice of Allowance for their DIFS™ patent represents a significant advancement in their non-invasive neuromodulation approach to addiction treatment. The technology's application across multiple substance use disorders (opioids, alcohol, cocaine, methamphetamine) targets a massive market with critical unmet needs.

The clinical significance lies in DIFS™ potentially offering an alternative treatment pathway without pharmaceuticals or invasive procedures. Current addiction treatment often relies on medication-assisted treatments that can have side effects, compliance issues, and sometimes substitutes one dependency for another. A non-invasive approach that modulates neural pathways associated with addiction could complement or potentially replace certain aspects of conventional treatment protocols.

However, investors should recognize that while patent protection is valuable, the path to commercialization remains lengthy. The article doesn't mention completed clinical trials or FDA clearance specifically for these substance use disorder applications. Nexalin will need to demonstrate efficacy through rigorous clinical studies before this technology can achieve widespread adoption in addiction treatment settings. The company's modest market capitalization ($36 million) suggests they'll need to carefully manage resources to advance this technology through regulatory hurdles.

Intellectual Property Specialist

This patent allowance significantly strengthens Nexalin's intellectual property foundation and creates potential barriers to competition in the neuromodulation space for addiction treatment. A Notice of Allowance essentially guarantees patent issuance, providing Nexalin with exclusive rights to the claimed technology for approximately 20 years from filing date.

The strategic value extends beyond mere protection - this patent likely creates multiple monetization pathways. Beyond directly commercializing products, Nexalin could pursue licensing agreements, technology partnerships, or even acquisition interest from larger medical device companies seeking innovative solutions in the addiction treatment market.

The patent's scope covering multiple substance use disorders (opioids, alcohol, cocaine, methamphetamine) is particularly valuable as it broadens potential applications rather than limiting the technology to a single indication. This versatility enhances the technology's commercial potential and provides multiple market entry points.

For a small-cap company like Nexalin, robust IP protection is often the most valuable asset, and this patent allowance adds significant intrinsic value that may not yet be fully reflected in their market capitalization. However, investors should monitor how effectively management leverages this IP through either direct commercialization or strategic partnerships to generate tangible returns from this intellectual asset.

Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and Methamphetamine

HOUSTON, TX, March 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled “Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD).”

This newly allowed patent covers Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, a non-invasive, drug-free approach designed to support individuals struggling with substance use disorder (SUD), including opioid use disorder (OUD), alcohol use disorder (AUD), and stimulant addiction, such as cocaine and methamphetamine use disorders. By delivering deep-brain stimulation at dynamic frequencies, DIFS technology has the potential to modulate neural pathways associated with addiction and withdrawal symptoms, offering a novel treatment pathway for those affected by various forms of substance dependence.

Mark White, CEO of Nexalin Technology, commented, “Receiving this Notice of Allowance from the USPTO is a major step in Nexalin’s ongoing mission to provide innovative, non-invasive solutions for some of the most urgent healthcare challenges. Substance use disorders continue to devastate families and communities worldwide, and we believe our DIFS technology has the potential to play a transformative role in improving treatment outcomes. This patent further expands our intellectual property portfolio and reinforces Nexalin’s position as a leader in advancing groundbreaking medical technology.”

Substance use disorders, including opioid addiction, alcoholism, and stimulant dependence remain significant public health emergencies, affecting millions of individuals worldwide. While medication-assisted treatment (MAT) and behavioral therapy remain standard approaches, they present challenges related to accessibility, reliance on pharmaceuticals, and potential side effects. Nexalin’s DIFS technology offers a drug-free, non-invasive alternative that may help ease withdrawal symptoms and support long-term recovery without the risks associated with traditional treatment options.

David Owens, CMO of Nexalin Technology, stated, “Substance use disorders represent one of the most pressing public health crises of our time. Nexalin is committed to advancing new solutions that address critical unmet medical needs. Our proprietary DIFS technology is designed to deliver precise, deep-brain stimulation without the use of drugs or invasive procedures, representing a potential paradigm shift in addiction treatment. With this newly allowed patent, we are further establishing Nexalin as a leader in pioneering non-invasive treatment solutions for neurological and mental health conditions.”

This latest patent builds upon Nexalin’s expanding intellectual property portfolio, which includes cutting-edge advancements in non-invasive brain stimulation for mental health, addiction, and neurological disorders. As Nexalin continues to develop next-generation solutions, the Company remains committed to providing breakthrough technologies that improve patient outcomes and redefine standards of care in mental health and addiction treatment.

For more information about Nexalin Technology and its innovative medical technology solutions, visit www.nexalin-usa.com.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

Forward-looking statements

This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements.  Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

FAQ

What is the new patent granted to Nexalin Technology (NXL) for substance use disorders?

Nexalin received a USPTO Notice of Allowance for their DIFS™ technology patent, covering non-invasive treatment of opioid, alcohol, cocaine, and methamphetamine use disorders.

How does Nexalin's (NXL) DIFS™ technology work for addiction treatment?

DIFS™ delivers deep-brain stimulation at dynamic frequencies to modulate neural pathways associated with addiction and withdrawal symptoms, offering a non-invasive, drug-free treatment approach.

What advantages does Nexalin's (NXL) DIFS™ technology offer over traditional addiction treatments?

DIFS™ provides a drug-free, non-invasive alternative that may help ease withdrawal symptoms without the accessibility challenges and side effects associated with traditional treatments.

What substance use disorders can be treated with Nexalin's (NXL) patented DIFS™ technology?

The technology is designed to treat opioid use disorder (OUD), alcohol use disorder (AUD), and stimulant addictions including cocaine and methamphetamine use disorders.